Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial.
Serruys PW, Foley DP, Höfling B, Puel J, Glogar HD, Seabra-Gomes R, Goicolea J, Coste P, Rutsch W, Katus H, Bonnier H, Wijns W, Betriu A, Hauf-Zachariou U, van Swijndregt EM, Melkert R, Simon R. Serruys PW, et al. Circulation. 2000 Apr 4;101(13):1512-8. doi: 10.1161/01.cir.101.13.1512. Circulation. 2000. PMID: 10747343 Clinical Trial.
Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT).
Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, Rensing BJ, Vos J, Stibbe J. Serruys PW, et al. Circulation. 1991 Oct;84(4):1568-80. doi: 10.1161/01.cir.84.4.1568. Circulation. 1991. PMID: 1833088 Clinical Trial.
Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
Hermans WR, Rensing BJ, Foley DP, Tijssen JG, Rutsch W, Emanuelsson H, Danchin N, Wijns W, Chappuis F, Serruys PW. Hermans WR, et al. Among authors: serruys pw. J Cardiovasc Pharmacol. 1993;22 Suppl 4:S45-57. J Cardiovasc Pharmacol. 1993. PMID: 7523772 Clinical Trial.
Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
Hermans WR, Foley DP, Rensing BJ, Serruys PW. Hermans WR, et al. Among authors: serruys pw. Am Heart J. 1994 Mar;127(3):483-94. doi: 10.1016/0002-8703(94)90654-8. Am Heart J. 1994. PMID: 8122593 Clinical Trial.
2,728 results